Abstract Search

10.7. Real world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670G system in the first 6 months

LH Messer , C Berget , T Vigers , L Pyle , C Geno , PR Wadwa , KA Driscoll , GP Forlenza

To read the full abstract: Pediatr Diabetes. 2020 Mar;21(2):319327. doi: 10.1111/pedi.12971. Epub 2020 Jan 3. PMID: 31885123Dissatisfaction with technologies, discontinuation of use and inappropriate adjustments of insulin pump settings pose important areas of concern in adolescents using diabetes technologies. This study searched for predictors of hybrid closed loop (HCL) discontinuation...

0 shares

ey0015.10-7 | Continuous glucose monitoring, insulin pumps and artificial pancreas | ESPEYB15

10.7 Closed-loop control during intense prolonged outdoor exercise in adolescents with T1DM: the artificial pancreas ski study

MD Breton , DR Cherñavvsky , GP Forlenza , MD DeBoer , J Robic , RP Wadwa , LH Messer , BP Kovatchev , DM Maahs

To read the full abstract: Diabetes Care. 2017;40:1644-1650Exercise is thought to lead to more stable metabolic control but may also be associated with an increased risk of hypoglycemia. The selection of sport disciplines does not differ between youngsters with diabetes and their healthy siblings. Also, patients with diabetes are not restricted in respect to their sporting activities but seem to enga...

0 shares

ey0020.8-1 | Clinical Trials – New Treatments | ESPEYB20

8.1. Effect of Verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: A randomized clinical trial

GP Forlenza , J McVean , RW Beck , C Bauza , R Bailey , B Buckingham , LA DiMeglio , JL Sherr , M Clements , A Neyman , C Evans-Molina , EK Sims , LH Messer , L Ekhlaspour , R McDonough , M Van Name , D Rojas , S Beasley , S DuBose , C Kollman , A Moran , CLVer Study Group

Brief summary: In this double-blind, randomized clinical trial conducted in 6 US centres, 88 children and adolescents (aged 717 years) with newly diagnosed type 1 diabetes (T1D) were randomized to either once-daily oral verapamil or placebo, within 1 month from diagnosis. Treatment with verapamil led to better stimulated C-peptide secretion at 52 weeks post-diagnosis, with levels 30% higher compared to placebo.Verapamil is a calcium channel blocker...

0 shares

ESPE Yearbook of Paediatric Endocrinology

10.7. Real world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670G system in the first 6 months

10.7 Closed-loop control during intense prolonged outdoor exercise in adolescents with T1DM: the artificial pancreas ski study

8.1. Effect of Verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: A randomized clinical trial

BiosciAbstracts